ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Legend Biotech Corporation and Encourages Investors with Losses of $100,000 to Contact the Firm

September 25, 2020 2:23 PM EDT | Source: Schall Law Firm

Los Angeles, California--(Newsfile Corp. - September 25, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Legend Biotech Corporation ("Legend" or "the Company") (NASDAQ: LEGN) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Legend issued a press release on September 21, 2020, disclosing that Company CEO Dr. Fangliang Zhang has been placed under residential surveillance by the Chinese government. The Company also admitted that the Chinese Customs Anti-Smuggling Department has inspected the offices of GenScript Biotech Corporation, the Company's majority shareholder. These inspections included Legend's offices, and are related to alleged violations of import and export regulations. Based on this news, shares of Legend fell by more than 17% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64649

info